Septerna SEPN
NASDAQ SEPN
$41.38 +0.62 (+1.52%)
As of: Oct 22, 2026 · 11:25 AM EDT

Septerna (SEPN) Return on Equity [ROE] (2024 - 2026)

Updated

Septerna (SEPN) reported Return on Equity [ROE] of -6.33% for Q2 2026, up 16.16 percentage points from -22.50% a year earlier and up 3.14 percentage points from the prior quarter.

Analysis

Septerna (SEPN) Return on Equity [ROE] (2024 - 2026) Analysis & Trends

For FY2025, Septerna posted Return on Equity [ROE] of -12.19%, up 25.43 percentage points from FY2024.

  • By year, Return on Equity [ROE] came in at -37.62% in FY2024.
  • Year over year, Return on Equity [ROE] has now increased in each of the last three quarters.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -9.48% (Q1 2026), -12.69% (Q4 2025) and -15.35% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,175.39 Bn 1,143.98 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 639.10 Bn 557.63 Bn 17.26 Bn 25.32%
3 AbbVie 502.70 Bn 475.81 Bn 12.70 Bn -
4 Merck 376.68 Bn 331.05 Bn 12.21 Bn 7.21%
5 Novartis Ag 304.33 Bn 268.32 Bn 11.24 Bn 31.52%
6 Astrazeneca 267.75 Bn 241.43 Bn 12.86 Bn 21.39%
7 Amgen 242.34 Bn 197.73 Bn 7.24 Bn 83.75%
8 Gilead Sciences 193.67 Bn 167.87 Bn 6.22 Bn -18.38%
9 Pfizer 172.62 Bn 119.27 Bn 10.94 Bn 4.97%
10 Septerna 1.86 Bn 278.60 Mn - -6.33%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6.33%
Mar 31, 2026 -9.48%
Dec 31, 2025 -12.69%
Sep 30, 2025 -15.35%
Jun 30, 2025 -22.50%
Mar 31, 2025 -19.34%
Dec 31, 2024 -43.41%
API Access

Septerna Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=SEPN&period=max&api_key=YOUR_API_KEY